Dr. Stover discusses research on UGN-102 in non–muscle-invasive bladder cancer

“UGN-102 may offer a patient-centered therapeutic approach, more patient centered than standard treatments like surgery,” says Angela M. Stover, PhD.

In this video, Angela M. Stover, PhD, shares the take-home message from the Journal of Urology study, “Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer,” for which she served as a study author. Stover is an assistant professor of health policy and management at the University of North Carolina, Chapel Hill.